Covered recipient · General Payments record
MAKAYLA LEWIS
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2023–2024
$247.73
- Reported across 12 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $145.18 | 8 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Axsome Therapeutics, Inc. | $28.93 | 1 |
| Vanda Pharmaceuticals Inc. | $20.76 | 1 |
| Sage Therapeutics, Inc. | $20.06 | 1 |
| GlaxoSmithKline, LLC. | $17.95 | 1 |
| ABBVIE INC. | $15.50 | 1 |
| Merck Sharp & Dohme Corporation | $15.21 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $13.59 | 1 |
| Novo Nordisk AS | $13.18 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (8)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.50 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104170120 | CMS |
| Axsome Therapeutics, Inc. | $28.93 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148300330 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $13.59 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086178048 | CMS |
| GlaxoSmithKline, LLC. | $17.95 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116087102 | CMS |
| Merck Sharp & Dohme LLC | $15.21 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141664574 | CMS |
| Novo Nordisk Inc | $13.18 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097253241 | CMS |
| Sage Therapeutics, Inc. | $20.06 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120391967 | CMS |
| Vanda Pharmaceuticals Inc. | $20.76 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133910404 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.